We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+29.88%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.78B
AUM Growth
+$40.3M
Cap. Flow
-$635M
Cap. Flow %
-22.8%
Top 10 Hldgs %
41.28%
Holding
156
New
21
Increased
23
Reduced
32
Closed
45

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$77.3M
2
ACHN
Achillion Pharmaceuticals
ACHN
+$35.7M
3
NVRO
NEVRO CORP.
NVRO
+$33M
4
VNDA icon
Vanda Pharmaceuticals
VNDA
+$23.3M
5
AGN
Allergan Inc
AGN
+$22.9M

Top Sells

Rank Stock Value
1
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$46M
2
ABBV icon
AbbVie
ABBV
+$44.3M
3
KITE
Kite Pharma, Inc.
KITE
+$36M
4
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$30.9M
5
WBA
Walgreens Boots Alliance
WBA
+$28.6M

Sector Composition

Rank Sector Weight
1 Healthcare 52.44%
2 Financials 2.69%
3 Technology 0.73%
4 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SAGE
51
DELISTED
Sage Therapeutics
SAGE
$9.61M 0.35%
262,625
-188,042
-42% -$7.01M
ICPT
52
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$9.42M 0.34%
60,393
-38,300
-39% -$7.07M
KITE
53
DELISTED
Kite Pharma, Inc.
KITE
$8.98M 0.32%
155,799
-856,199
-85% -$36M
PRQR icon
54
ProQR Therapeutics
PRQR
$247M
$8.23M 0.3%
380,000
-150,000
-28% -$2.28M
STRM
55
DELISTED
Streamline Health Solutions
STRM
$7.89M 0.28%
121,517
– –
TRNX
56
DELISTED
TORNIER N V SHARES (NLD)
TRNX
$7.37M 0.26%
288,971
-180,036
-38% -$4.59M
CNXR
57
DELISTED
Connecture, Inc.
CNXR
$7.21M 0.26%
+799,750
New +$7.17M
DSCI
58
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$6.72M 0.24%
721,546
+167,489
+30% +$1.46M
CDNA icon
59
CareDx
CDNA
$2.04B
$5.83M 0.21%
804,000
+229,000
+40% +$1.54M
ATEC icon
60
Alphatec Holdings
ATEC
$1.29B
$5.62M 0.2%
331,895
– –
LMNS
61
DELISTED
LUMENIS LTD CL B ORD SHS (ISR)
LMNS
$5.58M 0.2%
597,866
– –
BDSI
62
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$5.58M 0.2%
+464,083
New +$7.05M
RIGL icon
63
Rigel Pharmaceuticals
RIGL
$738M
$5.44M 0.2%
239,786
– –
AXGN icon
64
Axogen
AXGN
$2.14B
$5.41M 0.19%
1,507,824
+1,162,824
+337% +$3.4M
CASM
65
DELISTED
CAS Medical Systems, Inc.
CASM
$5.28M 0.19%
3,200,000
– –
FOMX
66
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$5.22M 0.19%
744,799
+298,347
+67% +$1.71M
SCYX icon
67
SCYNEXIS
SCYX
$41.2M
$4.99M 0.18%
6,250
-791
-11% -$559K
TVRD
68
Tvardi Therapeutics
TVRD
$26.2M
$4.72M 0.17%
13,155
+2,516
+24% +$810K
PFNX
69
DELISTED
Pfenex Inc.
PFNX
$4.49M 0.16%
625,640
-187,838
-23% -$1.42M
EGRX
70
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$4.41M 0.16%
284,653
– –
BEAT
71
DELISTED
BioTelemetry, Inc.
BEAT
$4.3M 0.15%
429,000
-399,400
-48% -$3.43M
WINT
72
DELISTED
Windtree Therapeutics Inc
WINT
$4.25M 0.15%
261,407
– –
GNCA
73
DELISTED
Genocea Biosciences, Inc.
GNCA
$4.23M 0.15%
75,532
+6,250
+9% +$427K
KBIO
74
DELISTED
KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE)
KBIO
$3.96M 0.14%
285,848
-98,524
-26% -$1.41M
THOR
75
DELISTED
THORATEC CORPORATION
THOR
$3.34M 0.12%
102,919
-220,217
-68% -$6.41M
1 2
3
4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q4 2014 Portfolio in Review

As of Q4 2014, Deerfield Management held 156 positions worth $2.78B, up 1.5% from $2.74B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Deerfield Management withdrew a net $635M in Q4 2014, closing 45 positions and reducing 32 holdings. Its most notable exit was MALLINCKRODT PUBLIC LIMITED COMPANY, an estimated $46M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 52% of assets, up from 47% a quarter earlier, followed by Financials and Technology.

Against the trend, Deerfield Management opened a new position in Achillion Pharmaceuticals worth $35.8M.

  • Deerfield Management's largest Q4 2014 buy was Achillion Pharmaceuticals: 2,920,300 shares worth $35.8M.
  • Deerfield Management added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2014, an estimated $77.3M increase.
  • Deerfield Management's biggest Q4 2014 reduction was Kite Pharma, Inc., cutting an estimated $36M.
  • Deerfield Management fully exited MALLINCKRODT PUBLIC LIMITED COMPANY in Q4 2014, selling an estimated $46M.
  • Deerfield Management's ten largest holdings make up 41% of its $2.78B portfolio in Q4 2014.
  • Deerfield Management opened 21 new positions and closed 45 in Q4 2014.
  • Deerfield Management's portfolio value rose 1.5% quarter-over-quarter to $2.78B.

Based on Deerfield Management's 13F filing for Q4 2014, filed 17 Feb 2015.